| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
STARLING REVIEW |  |
Division of Medical Sciences, IBR Building, 2nd floor, The Medical School, University of Birmingham, Birmingham B15 2TT, UK
(Requests for offprints should be addressed to K Boelaert; Email: k.boelaert{at}bham.ac.uk)
Thyroid disease is common, affecting around 2% of women and 0.2% of men in the UK. Our understanding of the effects of thyroid hormones under physiological circumstances, as well as in pathological conditions, has increased dramatically during the last two centuries and it has become clear that overt thyroid dysfunction is associated with significant morbidity and mortality. Both hypo-and hyperthyroidism and their treatments have been linked with increased risk from cardiovascular disease and the adverse effects of thyrotoxicosis in terms of osteoporosis risk are well established. Although the evidence suggests that successful treatment of overt thyroid dysfunction significantly improves overall survival, the issue of treating mild or subclinical hyper- and hypothyroidism remains controversial. Furthermore, the now well-established effects of thyroid hormones on neurodevelopment have sparked a whole new debate regarding the need to screen pregnant women for thyroid function abnormalities. This review describes the current evidence of the effects of thyroid hormone on the cardiovascular, skeletal and neurological systems, as well as the influence of thyroid diseases and their treatments on the development of malignancy. Furthermore we will describe some recent developments in our understanding of the relationship between thyroid status and health.
This article has been cited by other articles:
|
|
 |
|
  P. Haentjens, A. Van Meerhaeghe, K. Poppe, and B. Velkeniers Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies Eur. J. Endocrinol., September 1, 2008; 159(3): 329 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Taylor, J. Swant, J. J. Wagner, J. W. Fisher, and D. C. Ferguson Lower Thyroid Compensatory Reserve of Rat Pups after Maternal Hypothyroidism: Correlation of Thyroid, Hepatic, and Cerebrocortical Biomarkers with Hippocampal Neurophysiology Endocrinology, July 1, 2008; 149(7): 3521 - 3530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Samuels, K. G. Schuff, N. E. Carlson, P. Carello, and J. S. Janowsky Health Status, Mood, and Cognition in Experimentally Induced Subclinical Thyrotoxicosis J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1730 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meischl, H. P. Buermans, T. Hazes, M. J. Zuidwijk, R. J. P. Musters, C. Boer, A. van Lingen, W. S. Simonides, M. A. Blankenstein, C. Dupuy, et al. H9c2 cardiomyoblasts produce thyroid hormone Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1227 - C1233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kondrashova, H. Viskari, A.-M. Haapala, T. Seiskari, P. Kulmala, J. Ilonen, M. Knip, and H. Hyoty Serological Evidence of Thyroid Autoimmunity among Schoolchildren in Two Different Socioeconomic Environments J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Rangan, A A Tahrani, A F Macleod, and P K Moulik Once weekly thyroxine treatment as a strategy to treat non-compliance Postgrad. Med. J., October 1, 2007; 83(984): e3 - e3. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dong, C. L. Yauk, A. Williams, A. Lee, G. R. Douglas, and M. G. Wade Hepatic Gene Expression Changes in Hypothyroid Juvenile Mice: Characterization of a Novel Negative Thyroid-Responsive Element Endocrinology, August 1, 2007; 148(8): 3932 - 3940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.E. Okosieme, R.C. Taylor, A.E. Ohwovoriole, A.B. Parkes, and J.H. Lazarus Prevalence of thyroid antibodies in Nigerian patients QJM, February 1, 2007; 100(2): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Rae, O. Gubbay, A. Kostogiannou, D. Price, H. O. D. Critchley, and S. G. Hillier Thyroid Hormone Signaling in Human Ovarian Surface Epithelial Cells J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 322 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Tien, K. Matsui, R. Moore, and M. Negishi The Nuclear Receptor Constitutively Active/Androstane Receptor Regulates Type 1 Deiodinase and Thyroid Hormone Activity in the Regenerating Mouse Liver J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mascitelli and F. Pezzetta Erectile dysfunction and incidence of cardiovascular disease. JAMA, May 3, 2006; 295(17): 1998 - 1999. [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
